NLTX - Neoleukin Therapeutics Inc Stock Price, Fair Value and News

15.10USD Delayed

Market Summary

USD15.10

Delayed

NLTX Stock Price

View Fullscreen

NLTX RSI Chart

NLTX Valuation

Market Cap

178.6M

Price/Earnings (Trailing)

-4.58

EV/EBITDA

-0.9

Price/Free Cashflow

-2.98

MarketCap/EBT

-5.24

NLTX Price/Sales (Trailing)

NLTX Profitability

Return on Equity

-22.84%

Return on Assets

-19.97%

Free Cashflow Yield

-33.6%

NLTX Fundamentals

NLTX Earnings

Earnings (TTM)

-39.0M

Earnings Growth (Yr)

-18.98%

Earnings Growth (Qtr)

-9.02%

Breaking Down NLTX Revenue

Last 7 days

287.6%

Last 30 days

297.7%

Last 90 days

266.9%

Trailing 12 Months

555.2%

How does NLTX drawdown profile look like?

NLTX Financial Health

Current Ratio

14.74

NLTX Investor Care

Shares Dilution (1Y)

51.54%

Diluted EPS (TTM)

-117

Tracking the Latest Insider Buys and Sells of Neoleukin Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 05, 2023	baker bros. advisors lp	acquired	-	-	592,650	-
Aug 17, 2023	baker bros. advisors lp	bought	115,617	0.692559	166,942	-
Aug 16, 2023	baker bros. advisors lp	bought	156,254	0.680548	229,600	-
Aug 15, 2023	baker bros. advisors lp	bought	1,191,620	0.630885	1,888,800	-
Aug 11, 2023	smith sean michael	sold	-818	0.6184	-1,323	interim cfo, prin acct off
Aug 10, 2023	smith sean michael	acquired	-	-	5,000	interim cfo, prin acct off
Apr 03, 2023	patel priti	sold	-2,607	0.6919	-3,769	-
Mar 31, 2023	patel priti	acquired	-	-	10,000	-
Feb 02, 2023	patel priti	sold	-8,587	0.5972	-14,380	chief medical officer
Feb 02, 2023	smith sean michael	sold	-1,980	0.5972	-3,316	principal accounting officer

Which funds bought or sold NLTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Aug 09, 2023	Endurance Wealth Management, Inc.	sold off	-100	-14,000	-	-%
Nov 03, 2022	ACT CAPITAL MANAGEMENT, LLC	unchanged	-	-78,000	127,000	0.17%
Oct 17, 2022	Highland Private Wealth Management	unchanged	-	-18,000	30,000	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	9,000	9,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	added	7.17	-305,000	220,000	-%
Apr 04, 2022	Dixon Hughes Goodman Wealth Advisors LLC	new	-	-	-	-%
Aug 16, 2021	PICTET ASSET MANAGEMENT LTD	added	1.78	-5,856,000	18,865,000	0.02%

Are Funds Buying or Selling NLTX?

Are funds buying NLTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NLTX

No. of Funds

Unveiling Neoleukin Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	samsara biocapital, l.p.	9.99%	1,282,563	SC 13G
Feb 14, 2024	ecor1 capital, llc	9.99%	1,282,168	SC 13G
Feb 14, 2024	cormorant asset management, lp	1.21%	155,805	SC 13G
Feb 14, 2024	redmile group, llc	8.1%	1,050,304	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	0.1%	46	SC 13G/A
Feb 14, 2024	great point partners llc	7.75%	994,229	SC 13G/A
Feb 14, 2024	janus henderson group plc	6.6%	841,688	SC 13G
Dec 27, 2023	great point partners llc	7.56%	969,229	SC 13G
Dec 22, 2023	redmile group, llc	9.9%	1,282,661	SC 13G/A
Dec 21, 2023	mcminn rachel	9.9%	1,273,351	SC 13D

Recent SEC filings of Neoleukin Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Apr 22, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report

Peers (Alternatives to Neoleukin Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Neoleukin Therapeutics Inc News

Latest updates

Neoleukin Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.2%	195	223	90.00	94.00	98.00	109	127	137	149	163	176	187	200	211	222	145	153	147	70.00	74.00	75.00
Current Assets	-13.1%	174	200	80.00	84.00	86.00	85.00	109	118	130	144	156	167	181	195	207	131	140	144	68.00	73.00	75.00
Cash Equivalents	1.5%	150	148	25.00	31.00	35.00	82.00	41.00	78.00	129	71.00	156	165	179	193	202	130	140	143	66.00	73.00	74.00
Net PPE	-4.1%	16.00	17.00	0.00	1.00	2.00	20.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	4.00	3.00	3.00	2.00	2.00	1.00	0.00	0.00
Liabilities	-32.8%	25.00	37.00	14.00	14.00	17.00	11.00	21.00	20.00	19.00	20.00	21.00	20.00	21.00	19.00	21.00	17.00	16.00	5.00	3.00	1.00	4.00
Current Liabilities	-48.6%	12.00	23.00	5.00	5.00	7.00	7.00	10.00	9.00	8.00	9.00	9.00	8.00	8.00	8.00	10.00	6.00	6.00	5.00	3.00	1.00	4.00
Shareholder's Equity	-8.2%	171	186	75.00	80.00	81.00	94.00	106	117	130	143	155	167	179	191	200	129	137	142	67.00	72.00	72.00
Retained Earnings	-9.0%	-204	-187	-471	-467	-465	-150	-437	-424	-408	-393	-378	-362	-347	-332	-320	-317	-308	-299	-291	-232	-232
Additional Paid-In Capital	0.4%	375	373	547	547	547	5.00	543	541	539	536	533	530	527	524	521	447	445	441	358	305	304
Shares Outstanding	0.3%	13.00	13.00	9.00	9.00	9.00	9.00	11.00	11.00	11.00	8.00	11.00	11.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	33.00	-	-	-	36.00	-	-	-	323	-	-	-	546	-	-	-	24.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	28.0%	-21,650	-30,071	-4,269	-4,049	-13,033	-18,150	-9,289	-11,294	-14,091	-12,168	-8,756	-13,276	-13,358	-9,229	-112	-8,794	-6,440	-4,636	-6,532	-1,470	-2,756
Share Based Compensation	478.6%	1,045	-276	172	331	1,191	-5,537	2,031	2,312	2,446	3,009	3,210	2,918	2,420	2,229	1,688	1,022	683	666	5,151	788	1,078
Cashflow From Investing	76.5%	29,935	16,956	-1,614	-411	10,706	65,371	-27,850	-39,299	-452	-396	-587	-1,191	-1,089	-653	-487	-972	-107	-782	-	-	-
Cashflow From Financing	-107.0%	-6,524	92,843	-1.00	-294	-66.00	66,388	-52.00	62.00	133	107	32.00	311	282	1,288	72,156	301	3,390	82,204	37.00	-2.00	-2.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NLTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Operating expenses:

Research and development expenses

$ 13,541

$ 10,283

General and administrative expenses

5,238

2,752

Total operating expenses

18,779

13,035

Loss from operations

(18,779)

(13,035)

Other income (expense):

Interest income

2,320

777

Interest expense

(3)

(2)

Other income

143

Other expense

(602)

(3)

Net loss

$ (16,921)

(12,263)

Per share information

Net income (loss) per share, basic (in dollars per share)

^[1]

$ (1.00)

Net income (loss) per share, diluted (in dollars per share)

^[1]

$ (1.00)

Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares)

^[1]

16,903,735

Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares)

^[1]

16,903,735

Class A Common Stock

Other income (expense):

Net loss

$ (12,263)

Per share information

Net income (loss) per share, basic (in dollars per share)

^[1]

$ (28.28)

Net income (loss) per share, diluted (in dollars per share)

^[1]

$ (28.28)

Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares)

^[1]

433,623

Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares)

^[1]

433,623

Class B Common Stock

Other income (expense):

Net loss

$ 0

Per share information

Net income (loss) per share, basic (in dollars per share)

$ 0

Net income (loss) per share, diluted (in dollars per share)

$ 0

Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares)

Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares)

[1]	For the three months ended March 31, 2023, net loss per share information is presented for the Company’s then outstanding Class A common stock. For the three months ended March 31, 2024, net loss per share information is presented for the Company’s common stock.

NLTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 150,140	$ 148,210
Short-term investments	19,393	48,947
Prepaid expenses and other current assets	4,608	3,191
Total current assets	174,141	200,348
Property and equipment, net	16,475	17,174
Operating lease right-of-use assets	3,565	3,681
Finance lease right-of-use assets	87	98
Restricted cash	339	508
Other non-current assets	743	764
Total assets	195,350	222,573
Current liabilities:
Accounts payable	1,522	2,596
Accrued expenses and other current liabilities	6,824	17,495
Operating lease liabilities, current	2,670	2,559
Finance lease liabilities, current	43	42
Lease contingent value rights liability, current	430	281
Intellectual property contingent value rights liability	329	0
Total current liabilities	11,818	22,973
Operating lease liabilities, non-current	11,642	12,302
Finance lease liabilities, non-current	53	65
Lease contingent value rights liability, non-current	857	1,006
Other liabilities	203	203
Total liabilities	24,573	36,549
Stockholders' equity:
Preferred stock, $0.000001 par value; $50,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.000001 par value; $450,000,000 shares authorized as of March 31, 2024 and December 31, 2023; $12,860,995 and $12,823,665 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	374,852	373,178
Accumulated deficit	(204,075)	(187,154)
Total stockholders' equity	170,777	186,024
Total liabilities and stockholders' equity	$ 195,350	$ 222,573

About Neoleukin Therapeutics Inc

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

CEO	Ms. Donna M. Cochener-Metcalfe J.D.
WEBSITE	neoleukin.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Neoleukin Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Neoleukin Therapeutics Inc? What does NLTX stand for in stocks?

NLTX is the stock ticker symbol of Neoleukin Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neoleukin Therapeutics Inc (NLTX)?

As of Tue Apr 30 2024, market cap of Neoleukin Therapeutics Inc is 178.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NLTX stock?

You can check NLTX's fair value in chart for subscribers.

What is the fair value of NLTX stock?

You can check NLTX's fair value in chart for subscribers. The fair value of Neoleukin Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neoleukin Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NLTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neoleukin Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NLTX is over valued or under valued. Whether Neoleukin Therapeutics Inc is cheap or expensive depends on the assumptions which impact Neoleukin Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NLTX.